Curis Announces Presentations of CUDC-907 and Erivedge(R) Clinical Data at 2015 ASCO Annual Meeting

Curis, Inc.

, a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that clinical data from two programs will be presented at the Annual Meeting of American Society of Clinical Oncology (ASCO), being held from May 29 - June 2, 2015 in Chicago, IL. Curis' study investigators will present data from the Phase 1 study of CUDC-907, Curis' proprietary oral, dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor that is being studied in the ongoing expansion stage of a Phase 1 trial, with a focus on patients with relapsed/ refractory diffuse large B-cell lymphoma (DLBCL). The U.S. FDA recently granted Orphan Drug Designation to CUDC-907 for the treatment of DLBCL. Curis is also conducting a separate Phase 1 trial to investigate CUDC-907 in patients with advanced solid tumors, including those with advanced hormone receptor positive breast cancer or with NUT midline carcinoma. In addition, data will be presented from clinical studies of Erivedge®, a first-in-class hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma (BCC). Roche and Genentech, a member of the Roche Group, develop and commercialize